{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:55:56Z","timestamp":1781528156308,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107143","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:02:18Z","timestamp":1773676938000},"page":"107143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative assessment of treatment switching in patients with multiple sclerosis receiving cladribine tablets versus fingolimod, dimethyl fumarate, and teriflunomide"],"prefix":"10.1016","volume":"109","author":[{"given":"Carroline","family":"Lobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Gomez","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.107143_bib0001","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","article-title":"Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study","volume":"11","author":"Araujo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.msard.2026.107143_bib0002","doi-asserted-by":"crossref","first-page":"204","DOI":"10.17712\/nsj.2018.3.20180003","article-title":"Tolerability and discontinuation rates in teriflunomide-treated patients: a real-world clinical experience","volume":"23","author":"Alnajashi","year":"2018","journal-title":"Neurosciences"},{"key":"10.1016\/j.msard.2026.107143_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104791","article-title":"Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: a real-world study","volume":"76","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2026.107143_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"issue":"4","key":"10.1016\/j.msard.2026.107143_bib0005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek","year":"2010","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2026.107143_bib0006","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.msard.2026.107143_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2026.107143_bib0008","unstructured":"Dukkipati R., Negroski D., Gutierrez A., Marchand Col\u00f3n B., Mart\u00ednez Maldonado V., Chinea A. \"LBA06 - Efficacy and safety of cladribine tablets in a large US real-world multicenter population.\" Consortium of Multiple Sclerosis Centers (CMSC), Phoenix, Arizona, 28-31 May 2025. Oral presentation."},{"key":"10.1016\/j.msard.2026.107143_bib0009","unstructured":"FDA, 2019 approves new oral treatment for multiple sclerosis. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-treatment-multiple-sclerosis (accessed 10 August 2024)."},{"key":"10.1016\/j.msard.2026.107143_bib0010","unstructured":"Fact Sheet. IQVIA PharMetrics\u00ae Plus. IQVIA-PharMetrics-plus-US-fact-sheet.Pdf (accessed 02 Dec 2024)."},{"key":"10.1016\/j.msard.2026.107143_bib0011","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/WNL.96.15_supplement.1919","article-title":"CLASSIC-MS: long-term efficacy and real-world treatment patterns for patients with relapsing multiple sclerosis who received cladribine tablets in phase III parent trials (1919)","volume":"96","author":"Giovannoni","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107143_bib0012","unstructured":"Healthcare Map\u2122. https:\/\/www.komodohealth.com\/technology\/healthcare-map. (accessed 02 Dec 2024)."},{"key":"10.1016\/j.msard.2026.107143_bib0014","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1212\/WNL.0000000000203948","article-title":"Patient characteristics and persistence among commercially insured patients with multiple sclerosis initiating cladribine tablets (P14-3.001)","volume":"100","author":"Kozma","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107143_bib0015","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/PPA.S142373","article-title":"The impact of quality of life on treatment preferences in multiple sclerosis patients","volume":"11","author":"Lee Mortensen","year":"2017","journal-title":"Patient. Prefer. Adherence"},{"key":"10.1016\/j.msard.2026.107143_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107143_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"Mccool","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107143_bib0018","unstructured":"National Multiple Sclerosis Society. Medications. Available from: https:\/\/www.nationalmssociety.org\/managing-ms\/treating-ms\/treatments-and-medications. (accessed June 6, 2024)."},{"key":"10.1016\/j.msard.2026.107143_bib0019","unstructured":"National Multiple Sclerosis Society. Types of multiple sclerosis. https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS (accessed 10 August 2024)."},{"key":"10.1016\/j.msard.2026.107143_bib0020","unstructured":"National Multiple Sclerosis Society. MS Prevalence. https:\/\/www.nationalmssociety.org\/about-the-society\/who-we-are\/research-we-fund\/ms-prevalence (Accessed by 02 Dec 2024)."},{"issue":"2","key":"10.1016\/j.msard.2026.107143_bib0021","article-title":"Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis","volume":"7","author":"Norborg","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2026.107143_bib0022","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf","year":"2002","journal-title":"J. Manage Care Pharm."},{"issue":"2","key":"10.1016\/j.msard.2026.107143_bib0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107143_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1626317","article-title":"Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study","volume":"16","author":"Pogoda-Weso\u0142owska","year":"2025","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107143_bib0025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"issue":"7","key":"10.1016\/j.msard.2026.107143_bib0026","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2026.107143_bib0027","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1212\/WNL.90.15_supplement.P1.140","article-title":"Epidemiology of multiple sclerosis in the United States (P1.140)","volume":"90","author":"Sharma","year":"2018","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.msard.2026.107143_bib0028","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2026.107143_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107143_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107143_bib0031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107143_bib0032","series-title":"StatPearls [Internet]","article-title":"Multiple sclerosis","author":"Tafti","year":"2024"},{"key":"10.1016\/j.msard.2026.107143_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102539","article-title":"Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population","volume":"46","author":"Toliver","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107143_bib0034","article-title":"Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience","volume":"3","author":"Vollmer","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107143_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116498","article-title":"Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up","volume":"407","author":"Vollmer","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107143_bib0036","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:24:46Z","timestamp":1781526286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"alternative-id":["S2211034826001793"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107143","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative assessment of treatment switching in patients with multiple sclerosis receiving cladribine tablets versus fingolimod, dimethyl fumarate, and teriflunomide","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107143"}}